Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 1/20 | 0.42 |
| ▸ | AHR | P35869 | 2/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 3/20 | 0.32 |
| ▸ | DRD3 | P35462 | 3/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
| ▸ | DRD1 | P21728 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3064096 | 0.74 | SCN5A (0.42) | SCN5APIK3CDDYRK1ACYP11B1CYP11B2 | |
| SCHEMBL12489513 | 0.74 | SCN5A (0.42) | SCN5APIK3CDDYRK1ACYP11B1CYP11B2 | |
| SCHEMBL3089077 | 0.74 | SCN5A (0.42) | SCN5APIK3CDDYRK1ACYP11B1CYP11B2 | |
| SCHEMBL3076621 | 0.74 | SCN5A (0.42) | SCN5APIK3CDDYRK1ADRD4DRD3 | |
| SCHEMBL24449040 | 0.74 | SCN5A (0.42) | SCN5APIK3CDDYRK1ADRD4DRD3 | |
| SCHEMBL24215352 | 0.74 | SCN5A (0.40) | SCN5APIK3CDDYRK1ADRD4DRD3 | |
| SCHEMBL13212874 | 0.71 | SCN5A (0.59) | SCN5APIK3CDCYP11B1CYP11B2 | |
| SCHEMBL28275420 | 0.70 | MAP4K4 (0.35) | AHRCYP1A2CYP2C19HTTNPC1 | |
| SCHEMBL12603995 | 0.69 | SCN5A (0.43) | SCN5APIK3CDDRD4DRD3ESR1 | |
| SCHEMBL24782798 | 0.69 | SCN5A (0.40) | SCN5APIK3CDESR1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026098632-A1 | HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2026-05-15 | — | — | WO | disclosed |
| EP-4741391-A1 | NMT INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Nanjing Synnocare Pharmaceutical Technology Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| EP-4737449-A1 | P53-Y220C SELECTIVE SMALL-MOLECULAR REACTIVATOR COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Changchun Genescience Pharmaceutical Co., Ltd. (CN) | 2026-05-06 | — | — | EP | disclosed |
| EP-4727940-A1 | DIHYDROPYRIMIDINE-2, 4 (1H, 3H) -DIONE-CONTAINING POLYCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREOF AND USE THEREOF | Linkcure Therapeutics (KY) | 2026-04-22 | — | — | EP | disclosed |
| EP-4716532-A2 | BICYCLIC HETEROARYL COMPOUNDS | Quantx Biosciences US, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20260049080-A1 | WILD TYPE KIT INHIBITORS | BLUEPRINT MEDICINES CORP (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4262788-B1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12522595-B2 | Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2026-01-13 | — | — | US | disclosed |
| EP-4658656-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | Beone Medicines I GmbH (CH) | 2025-12-10 | — | — | EP | disclosed |
| US-20250346597-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | BEONE MEDICINES I GMBH (CH) | 2025-11-13 | — | — | US | disclosed |
| WO-2015095767-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF | 3-V BIOSCIENCES, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| EP-2870150-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V Biosciences, Inc. (US) | 2015-05-13 | — | — | EP | disclosed |
| WO-2014130375-A1 | HETEROAROMATIC COMPOUNDS AS PI3 KINASE MODULATORS | CALITOR SCIENCES, LLC (US) | 2014-08-28 | — | — | WO | disclosed |
| US-20140234254-A1 | HETEROAROMATIC COMPOUNDS AS PI3 KINASE MODULATORS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-08-21 | — | — | US | disclosed |
| WO-2014078802-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014008197-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. (US) | 2014-01-09 | — | — | WO | disclosed |
| WO-2014008197-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. (US) | 2014-01-09 | — | — | WO | disclosed |
| US-20100226881-A1 | PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-09-09 | — | — | US | disclosed |
| EP-2176260-A1 | PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009008748-A1 | PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049080-A1 | WILD TYPE KIT INHIBITORS | KIT, CSNK1A1, CSNK1A1L | SCN5A 86/4885AHR 3050/4885PIK3CD 291/4885 |
| US-20100226881-A1 | PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY | TP53, PNPO, DPYD | SCN5A 2888/4885AHR 767/4885PIK3CD 1820/4885 |
| US-20250346597-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | DGKG, DGKA, DGKK | SCN5A 4747/4885AHR 3105/4885PIK3CD 111/4885 |
| US-20140234254-A1 | HETEROAROMATIC COMPOUNDS AS PI3 KINASE MODULATORS AND METHODS OF USE | PIK3R1, PIK3R3, AKT3 | SCN5A 4513/4885AHR 2404/4885PIK3CD 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.